Neurocrine Biosciences (NASDAQ:NBIX) will be announcing its earnings results after the market closes on Monday, February 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at $79.28 on Friday. The firm has a market cap of $7,020.00, a P/E ratio of -35.71, a PEG ratio of 13.72 and a beta of 0.26. Neurocrine Biosciences has a one year low of $39.21 and a one year high of $91.82. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
In related news, Director Gary A. Lyons sold 5,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $83.08, for a total transaction of $415,400.00. Following the completion of the sale, the director now directly owns 267,066 shares of the company’s stock, valued at $22,187,843.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gary A. Lyons sold 10,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the sale, the director now directly owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,707 shares of company stock valued at $14,975,715. Company insiders own 4.80% of the company’s stock.
A number of analysts have recently weighed in on NBIX shares. Robert W. Baird reaffirmed a “buy” rating and issued a $84.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Needham & Company LLC upped their price target on shares of Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $76.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Oppenheimer set a $95.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Monday, January 15th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $82.31.
COPYRIGHT VIOLATION NOTICE: “Neurocrine Biosciences (NBIX) to Release Quarterly Earnings on Monday” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/10/neurocrine-biosciences-nbix-to-release-quarterly-earnings-on-monday.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.